This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2005
Title: John Franklin Beattie: Innovator in Pharmaceutical Chemistry
Introduction
John Franklin Beattie is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds that target cell cycle kinases.
Latest Patents
John Franklin Beattie holds a patent for "Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives." This patent describes a compound of formula (I) wherein Ring A is imidazol[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl. The patent details the use of these compounds in the inhibition of cell cycle kinases CDK2, CDK4, and CDK6. Additionally, it outlines pharmaceutical compositions, methods, and processes for the preparation of these compounds. He has 1 patent to his name.
Career Highlights
John Franklin Beattie is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work focuses on the development of innovative therapeutic solutions that address critical health challenges.
Collaborations
He has collaborated with notable coworkers, including Andrew Peter Thomas and Gloria Anne Breault, contributing to advancements in pharmaceutical research and development.
Conclusion
John Franklin Beattie is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of various diseases. His innovative compounds and collaborations highlight his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile